Daily Cardiology Research Analysis
Analyzed 224 papers and selected 3 impactful papers.
Summary
Analyzed 224 papers and selected 3 impactful articles.
Selected Articles
1. Ratio of Left Atrial and Ventricular Volume as New Marker of Atrial Cardiopathy and Stroke Risk.
Across UK Biobank and an ischemic stroke cohort, the LA:LV volume ratio outperformed LAVi as a marker of atrial cardiopathy. LA:LV ratio was associated with incident ischemic stroke/TIA, cognitive function, and better identification of AF/flutter as stroke etiology, whereas LAVi was not significantly linked to stroke/TIA risk.
Impact: Introduces a specific, physiology-adjusted volumetric ratio that better captures pathological atrial remodeling linked to cerebrovascular and cognitive outcomes.
Clinical Implications: LA:LV ratio from cardiac imaging could refine risk stratification for embolic stroke and guide targeted rhythm monitoring and preventive strategies beyond LAVi alone.
Key Findings
- In UK Biobank, LAVi was not significantly associated with incident ischemic stroke/TIA, whereas LA:LV ratio was associated with these outcomes.
- LA:LV ratio correlated with cognitive function measures, supporting its link to broader atrial cardiopathy sequelae.
- In a stroke cohort, LA:LV ratio better identified atrial fibrillation/flutter as the stroke mechanism compared with LAVi.
Methodological Strengths
- Two independent cohorts, including a large, population-based sample (n=38,848) and a clinical stroke cohort.
- Use of competing risks survival analysis and multivariable modeling to assess associations robustly.
Limitations
- Observational design limits causal inference and residual confounding cannot be excluded.
- Volumes derived from cardiac MRI may limit generalizability to routine echocardiography workflows; thresholds need echo-based validation.
Future Directions: Prospective validation of LA:LV ratio thresholds in echocardiography, integration into stroke risk calculators, and testing whether LA:LV-guided strategies improve detection of subclinical AF and reduce embolic events.
BACKGROUND: Atrial cardiopathy is an important cause of embolic stroke and a potential cause of cognitive impairment. Increased left atrial volume indexed to body surface area (LAVi) has been widely used as a marker for atrial cardiopathy. However, because physiological remodeling, for example, due to exercise, may also increase LAVi, it lacks specificity. Left atrial to ventricular volume (LA:LV) ratio has been suggested as an improved marker of atrial cardiopathy, allowing detection of imbalanced, pathological atrial remodeling. We investigated if LA:LV ratio is associated with different sequelae of atrial cardiopathy. METHODS: We analyzed data from 2 cohorts, the population-based UK Biobank cohort (n=38 848) and a cohort of patients with ischemic stroke from the University Hospital Zürich (n=1273). In the UK Biobank cohort, we compared the association of LAVi and LA:LV ratio with risk of incident ischemic stroke or transient ischemic attack ascertained from linked health records, using competing risks survival analysis. We also investigated the association with cognitive function using linear regression models. In the ischemic stroke patient cohort, we compared LAVi and LA:LV ratio for identifying atrial fibrillation/flutter as a cause of stroke. RESULTS: While LAVi was not significantly associated with risk of ischemic stroke/transient ischemic attack (aHR, 1.11 [95% CI, 0.97-1.26]; CONCLUSIONS: We provide evidence that LA:LV ratio is a strong, novel marker of atrial cardiopathy. Hence, LA:LV ratio has the potential to improve the diagnosis of atrial cardiopathy, facilitating the prophylaxis of ischemic stroke and maintaining brain health.
2. Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With Trial Sequential Analysis.
Across 19,826 post-MI patients with LVEF ≥40%, beta-blockers did not reduce primary outcomes in those with preserved EF, with TSA indicating conclusive futility. In contrast, patients with mildly reduced EF (40–49%) showed reduced MACE with beta-blockers, warranting confirmation in dedicated RCTs.
Impact: Clarifies a long-standing uncertainty about post-MI beta-blocker use in preserved EF and leverages trial sequential analysis to establish futility. This stratified evidence can realign guideline recommendations and de-prescribing strategies.
Clinical Implications: Consider de-escalation or selective use of beta-blockers after MI when LVEF is ≥50%, while prioritizing treatment in mildly reduced EF (40–49%) pending confirmatory RCTs. Shared decision-making should incorporate EF strata and patient-specific risks.
Key Findings
- In 19,826 post-MI patients (17,941 preserved EF; 1,885 mildly reduced EF), beta-blockers did not reduce the primary endpoint overall in preserved EF (HR 0.92, 95% CI 0.85–1.01; p=0.08).
- Trial sequential analysis indicated conclusive futility of beta-blockers in preserved EF (LVEF ≥50%).
- Beta-blockers were associated with reduced MACE in mildly reduced EF (40–49%), requiring confirmation in adequately powered RCTs.
Methodological Strengths
- Time-to-event meta-analysis of randomized controlled trials with LVEF-stratified analyses.
- Trial sequential analysis to establish required information size, significance, and futility boundaries.
Limitations
- Abstract truncation limits detail on heterogeneity (I2) and endpoint definitions across trials.
- Lack of patient-level data may obscure subgroup interactions and dosing effects.
Future Directions: Conduct adequately powered RCTs focused on LVEF 40–49% to confirm benefits and define optimal duration/dosing; explore patient-level meta-analyses to refine subgroup effects.
AIMS: We aimed to evaluate the efficacy of β-blockers after myocardial infarction (MI) across left ventricular ejection fraction (LVEF) strata and to assess the conclusiveness of the available evidence using trial sequential analysis (TSA). METHODS: PubMed, Embase and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) evaluating β-blockers in post-MI patients with LVEF ≥ 40%. A time-to-event meta-analysis was performed for the primary composite (as defined by each trial) and for individual endpoints. The Mantel-Haenszel method was used to pool risk ratios (RR) for major adverse cardiovascular events (MACE; death, MI or heart failure), including LVEF-stratified analyses. TSA estimated the required information size (RIS) and generated adjusted significance and futility boundaries, assuming a 5% type I error and 90% power. RESULTS: Across 19,826 post-MI patients (17,941 with LVEF ≥ 50% and 1885 with LVEF 40%-49%), β-blockers did not reduce time to the primary endpoint (HR 0.92, 95% CI 0.85-1.01; p = 0.08; I CONCLUSIONS: β-blockers conferred no benefit in post-MI patients with preserved LVEF, with conclusive evidence of futility, whereas therapy was associated with reduced MACE in those with mildly reduced LVEF, pending confirmation in further adequately powered randomized trials.
3. Apelin analog treatment reverses severe pulmonary arterial hypertension and right ventricular heart failure.
In a severe sugen‑hypoxia rat model of PAH, an enzyme-resistant apelin analog reversed pulmonary vascular lesions, nearly normalized pulmonary pressures, and restored right ventricular structure and function. Single‑nucleus RNA‑seq indicated rebalancing of protective BMPR2 versus pathogenic TGFBR2 signaling across lung and RV cell types.
Impact: Demonstrates disease reversal with a mechanism-linked peptide therapy and multi-omic validation, addressing a major unmet need in PAH and right heart failure.
Clinical Implications: Supports progressing to early-phase clinical trials of apelin analogs in PAH/RV failure and suggests pathway biomarkers (BMPR2/TGFBR2 balance) for pharmacodynamic monitoring.
Key Findings
- Apelin analog therapy corrected pulmonary vascular lesions and nearly normalized pulmonary arterial pressures in a severe PAH model.
- Right ventricular dilation/dysfunction and cardiorenal changes were reversed alongside deactivation of pathogenic cellular programs.
- Single-nucleus RNA-seq revealed restoration of protective BMPR2 signaling and attenuation of excessive TGFBR2 activity in lung and RV tissues.
Methodological Strengths
- Use of a rigorous, clinically relevant sugen-hypoxia PAH model with advanced disease.
- Integrated multi-omic profiling (single-nucleus RNA-seq) linking phenotype reversal to pathway rebalancing.
Limitations
- Preclinical animal study; human efficacy, dosing, and safety remain to be established.
- Single disease model and limited long-term toxicity/ durability data.
Future Directions: Phase I/II trials assessing safety, dosing, and hemodynamic efficacy; exploration of combination strategies with current PAH therapies and biomarker-guided patient selection.
Pulmonary arterial hypertension (PAH) is a progressive vascular syndrome characterized by aberrant signaling, severe pulmonary artery remodeling, and right ventricular (RV) failure, a major driver of morbidity and mortality. Dysregulation of the apelinergic pathway has been implicated in pulmonary vascular remodeling in PAH. Using a sugen-hypoxia rat model of PAH, we assessed the ability of a novel apelin analog, resistant to native peptidase degradation, to reverse the pathological hallmarks of PAH and RV dysfunction. Apelin analog therapy corrected the vascular lesions in the lungs and nearly normalized pulmonary arterial pressures. Early cardiorenal syndrome, RV dilation and dysfunction as well as RV cardiomyocyte and fibroblast activation induced by pressure overload, were also reversed by apelin analog treatment. Single-nucleus RNA sequencing of the lungs and RV revealed apelin-analog treatment activated several protective pathways, including rebalancing protective BMPR2 (bone morphogenetic protein receptor type 2) signaling to counteract excessive pathogenic TGFBR2 (transforming growth factor β receptor 2) activity in PAH. These findings highlight the therapeutic potential of exogenous apelin in reversing pulmonary vascular and cardiac pathologies in PAH and support further investigation to evaluate the clinical benefits of apelin analog treatment in patients with PAH and RV failure.